论文部分内容阅读
目的:探究氟罗沙星贯序法在泌尿系统疾病感染的相关治疗过程中所呈现的成本-效果分析,为临床应用提供参考。方法:选取2012年12月-2014年12月的泌尿系统感染患者180例,随机分为对照组和观察组,每组90例。其中,对照组使用静脉滴注输液法进行治疗,观察组使用氟罗沙星贯序法进行治疗,对比分析两组患者的药物经济学情况。结果:对照组和观察组的在治疗过程中显示的临床疗效等比较,差异均无统计学意义(P>0.05),但对照组所负担的治疗费高于观察组(P<0.05)。结论:相比较于静脉滴注输液来说,氟罗沙星贯序有较好的可实施性,不仅能够使患者得到有效治疗,还符合药物经济学原理,提高患者的依从性。
Objective: To explore the cost-effectiveness analysis of fleroxacin sequential method in the treatment of urinary tract infections and provide a reference for clinical application. Methods: 180 patients with urinary tract infection from December 2012 to December 2014 were randomly divided into control group and observation group, with 90 cases in each group. Among them, the control group was treated by intravenous drip infusion, and the observation group was treated by fleroxacin sequential method. The pharmacoeconomics of the two groups was compared. Results: There was no significant difference between the control group and the observation group in clinical efficacy (P> 0.05). However, the treatment cost of the control group was higher than that of the observation group (P <0.05). CONCLUSIONS: Compared with intravenous drip infusion, fleroxacin has a better operative procedure, which can not only effectively treat patients but also accord with the principles of pharmacology and improve patient compliance.